Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10910865 | Lung Cancer | 2015 | 37 Pages |
Abstract
Patritumab in combination with erlotinib was well tolerated and the efficacy of the combination was encouraging, especially in patients where prior gefitinib treatment failed.
Keywords
EGFR-TKIORRECoGMTDDCRDLTCTCAEAUCErlotinibHERstable diseaseprogressive diseaseELISAEnzyme-linked immunosorbent assayMaximum tolerated doseRECISTdose-limiting toxicityNSCLCNon-small cell lung cancereastern cooperative oncology groupAdverse eventsResponse Evaluation Criteria in Solid TumorsCommon Terminology Criteria for Adverse Eventsarea under the curveoverall response rateDisease control ratePartial responsehuman epidermal growth factor receptorEpidermal growth factor receptor-tyrosine kinase inhibitor
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Makoto Nishio, Atsushi Horiike, Haruyasu Murakami, Nobuyuki Yamamoto, Hiroyasu Kaneda, Kazuhiko Nakagawa, Hidehito Horinouchi, Masaki Nagashima, Masaru Sekiguchi, Tomohide Tamura,